Zymeworks授权新的1.25亿美元股票回购

2026-05-15 04:18

Zymeworks (ZYME) on Thursday said its board approved a new 2026 share repurchase program authorizing the company to buy back up to $125M of its common stock.
The biotechnology company also terminated its prior 2025 repurchase plan, under which it repurchased about 4.2M shares for $102.3M at an average price of $24.36 per share.
CEO Kenneth Galbraith said the new authorization reflects Zymeworks’ focus on disciplined capital allocation while maintaining flexibility to invest in its research pipeline and strategic opportunities.
The company said it had about 73M shares outstanding as of May 13, 2026.
Stock up 2% in aftermarket trading.

More on Zymeworks